Ipsen (FR:IPN) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ipsen’s Bylvay® demonstrates promising long-term efficacy and safety in treating rare cholestatic liver diseases, including PFIC and ALGS, with significant improvements in symptoms such as itch severity and serum bile acid levels over 72 weeks. The treatment has also shown benefits in patient growth and sleep quality, with most adverse events reported as mild or moderate. Ipsen aims to lead advancements in managing these challenging conditions.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.